Jung H, Hurtado M, Sanchez M, Medina M T, Sotelo J
Laboratory of Neuropharmacology, National Institute of Neurology and Neurosurgery of Mexico, Mexico City.
Clin Neuropharmacol. 1990 Dec;13(6):559-64. doi: 10.1097/00002826-199012000-00008.
Albendazole or praziquantel were measured in plasma and cerebrospinal fluid (CSF) in 29 patients with neurocysticercosis. Mean levels of albendazole in plasma were 0.918 microgram/ml and in CSF were 0.392 microgram/ml and levels of praziquantel were 1.640 micrograms/ml in plasma and 0.398 microgram/ml in CSF, after doses of 15 and 50 mg/kg, respectively. Drug concentrations in CSF were 43% for albendazole and 24% for praziquantel. The drug levels obtained for both drugs showed ample individual variations that were not related to age, sex, presence of inflammation in the subarachnoid space, or therapeutic effectiveness; such variations seem to be due to individual differences in pharmacokinetics. Both drugs were effective and the doses currently used of each drug seem to be optimal for therapy of neurocysticercosis.
对29例神经囊尾蚴病患者的血浆和脑脊液（CSF）中的阿苯达唑或吡喹酮进行了测定。分别给予15和50mg/kg剂量后，血浆中阿苯达唑的平均水平为0.918微克/毫升，脑脊液中为0.392微克/毫升；血浆中吡喹酮的水平为1.640微克/毫升，脑脊液中为0.398微克/毫升。脑脊液中阿苯达唑的药物浓度为43%，吡喹酮为24%。两种药物获得的药物水平均显示出较大的个体差异，这些差异与年龄、性别、蛛网膜下腔炎症的存在或治疗效果无关；这种差异似乎是由于药代动力学的个体差异所致。两种药物均有效，目前使用的每种药物剂量似乎是治疗神经囊尾蚴病的最佳剂量。
